Quote:

---

If Ohm can help the company -- for example, help Jay figure out the discrepancies between the 350 and 700 arms in the MASH trial, which would be of great use in screening for future trials -- and it means he posts less here, that's just fine.

---

The current mouse study should give some indication as there would be no CCR5 deletions in either the 350mg or 700mg arm. The FDA would certainly allow us to exclude any double allele CCR5 deletion in a human trial. For best possible trial outcome both single allele and double allele deletions should be excluded but the FDA might frown upon that.